Bioatla (BCAB) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Mar, 2026Executive summary
Special meeting of stockholders scheduled for March 4, 2026, will be adjourned and reconvened virtually on March 23, 2026, to vote on key proposals.
Main agenda includes approval of a merger between the company and its wholly owned subsidiary, BA Merger Sub, Inc.
Amendment No. 1 to the Merger Agreement ensures the company's certificate of incorporation remains unchanged post-merger.
Board of Directors unanimously recommends voting in favor of both the Merger Proposal and the Adjournment Proposal.
Only stockholders of record as of February 2, 2026, are entitled to vote at the meeting.
Voting matters and shareholder proposals
Stockholders will vote on the Merger Proposal and the Adjournment Proposal.
Approval of the Merger Proposal requires a majority of outstanding shares.
Proposals are now considered routine, allowing brokers to vote shares held in street name without owner instructions.
Proxies previously submitted will be voted as instructed unless revoked or changed before the meeting.
Voting can be done by proxy card, phone, internet, or electronically during the meeting.
Board of directors and corporate governance
The Board of Directors approved Amendment No. 1 to the Merger Agreement.
Board continues to recommend voting “FOR” both proposals.
Jay M. Short, Ph.D., serves as CEO and Chairman of the Board.
Latest events from Bioatla
- Shareholders to vote on a 1-for-50 share consolidation to address Nasdaq listing compliance.BCAB
Proxy Filing11 Feb 2026 - Q2 2024 saw reduced net loss, clinical milestones, and cash runway through Q3 2025.BCAB
Q2 20242 Feb 2026 - Promising clinical data and pivotal trial plans drive optimism for CAB-based cancer therapies.BCAB
Jefferies 2024 Global Healthcare Conference31 Jan 2026 - Vote on a 1-for-50 share consolidation merger to regain Nasdaq compliance and update governance.BCAB
Proxy Filing30 Jan 2026 - iNKT cell therapies show promise in cancer and ARDS, with pivotal trials and new programs underway.BCAB
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Up to $200M in securities offered, with $18.75M in equity deals to fund R&D and operations.BCAB
Registration Filing16 Jan 2026 - Stockholders will vote on a board-discretionary reverse stock split at the January 2026 meeting.BCAB
Proxy Filing15 Jan 2026 - Q3 2024 saw clinical progress, reduced losses, and a licensing deal extending cash runway to 2026.BCAB
Q3 202415 Jan 2026 - Stockholders are urged to vote on a board-discretionary reverse stock split by January 12, 2026.BCAB
Proxy Filing31 Dec 2025